RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.08 per share when it actually produced a loss of $0.08, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates two times.RenovoRx, which belongs to the Zacks Medical - Bio ...

RenovoRx (RNXT) Q2 2025 Earnings Call August 14, 2025 04:30 PM ET Speaker0Good afternoon. I'll be your conference call operator today. Please note that today's call is being recorded and all participants other than management are in a listen only mode. There will be a Q and A session following management's presentation. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications.Please go ahead.Speaker1Thank you, operator, and good afternoon. Welcome everyone to the Ren ...

Exhibit 99.1 RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review Revenue from RenovoCath device totaled over $400,000 for the Second Quarter 2025 MOUNTAIN VIEW, Calif. – August 14, 2025 – RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 001-40738 RENOVORX, INC. (Exact name of registrant as specified in its charter) (Registrant's telephone number, in ...

RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology procedures RenovoRx hires Senior Director of Sales and Market Development to coordinate, execute, and expand commercialization strategy MOUNTAIN VIEW, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or th ...

Summary of RenovoRx (RNXT) Conference Call - May 21, 2025 Company Overview - RenovoRx specializes in localized chemotherapy delivery through its patented device, RenovoCath, which utilizes a method called transarterial microperfusion (TAMP) [1][2] - The company has received orphan drug designation for its drug-device combination product in two indications, with a focus on pancreatic and bile duct cancers [2][20] Core Points and Arguments - **Commercialization and Revenue Generation**: RenovoRx has begun commercializing its device, generating approximately $200,000 in revenue during its first full quarter of sales [15][18] - **Market Potential**: The potential peak revenue for the device in the U.S. is estimated at $400 million, with an initial target market of around 7,000 patients [3][6] - **Clinical Trials**: The company is conducting a pivotal phase three trial (TIGER PACT) for its drug-device combination, with positive interim results indicating a 65% reduction in side effects compared to traditional systemic chemotherapy [23][29] - **Physician Interest**: There is significant inbound interest from physicians, particularly for treating patients with pancreatic cancer, as the device offers a less toxic alternative to traditional chemotherapy [11][12][14] Financial and Growth Strategy - **Sales Strategy**: RenovoRx plans to leverage a small sales team to target approximately 200 high-volume cancer treatment centers in the U.S., minimizing the need for a large sales force [7][18] - **Revenue Growth Potential**: Each patient treated could represent multiple device sales, with potential revenues ranging from $6,000 to $9,000 per device, leading to significant revenue growth opportunities [17][18] - **Funding Research and Development**: The revenue from the catheter sales is expected to fund ongoing research and development activities, potentially leading to cash flow positivity [21][18] Clinical and Competitive Advantages - **Reduced Side Effects**: The localized delivery mechanism significantly reduces systemic side effects associated with traditional chemotherapy, improving patient quality of life [23][24] - **Survival Benefits**: Early data from trials suggest that patients may experience longer survival rates due to the effective delivery of chemotherapy directly to tumors [25][29] Upcoming Catalysts - **Second Interim Analysis**: The second interim analysis of the TIGER PACT trial is expected in the third quarter of 2025, which will provide further insights into the trial's progress and potential outcomes [30][32] - **Insider Confidence**: Management has shown confidence in the company's future by purchasing shares in the open market, indicating belief in the company's undervaluation [34] Additional Insights - **Market Positioning**: RenovoRx is positioned favorably compared to analogs like Delcath and NovoCure, with management believing the company is undervalued in the current market [34] - **Optionality in Strategy**: The company has the flexibility to pivot between focusing on catheter sales or advancing drug-device combinations based on market conditions and trial outcomes [22]

Core Viewpoint - RenovoRx, Inc. is conducting its Q1 2025 earnings conference call, highlighting its financial and operational performance, with key leadership present to discuss the company's progress and future outlook [1][2]. Group 1: Company Leadership and Structure - The conference call features RenovoRx's leadership team, including Dr. Ramtin Agah (Founder and Chief Medical Officer), Shaun Bagai (CEO), and Ronald Kocak (VP Controller and Principal Accounting Officer) [2]. Group 2: Forward-Looking Statements - The company emphasizes that statements made during the call may be considered forward-looking, reflecting management's current views on market conditions and potential outcomes of clinical trials [3][4]. - Management's forward-looking statements are based on current plans and assumptions, which are subject to various risks and uncertainties [3].

Company Performance - RenovoRx, Inc. reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.07 per share a year ago [1] - The company posted revenues of $0.2 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.50%, and this is an increase from zero revenues a year ago [2] - RenovoRx shares have declined approximately 18.6% since the beginning of the year, while the S&P 500 has gained 0.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.32 million, and for the current fiscal year, it is -$0.30 on revenues of $1.55 million [7] - The estimate revisions trend for RenovoRx is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which RenovoRx belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

RenovoRx (RNXT) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Valter Pinto - Managing DirectorRamtin Agah - Chief Medical Officer & FounderShaun R. Bagai - CEORonald B. Kocak - VP Controller & Principal Accounting Officer Conference Call Participants None - Analyst Operator Good afternoon, everyone, and welcome to the Renovo Rx q one twenty twenty five financial and operational highlights conference call. All participants will be in a listen only mode. After today's presentation, there ...

RenovoRx (RNXT) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and welcome to the Renovo Rx q one twenty twenty five financial and operational highlights conference call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press and then 1 on your touch tone phones. To withdraw your questions, you may press and 2. Please also note today's event is being recorded. At this time, ...